Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform
Japanese patent issuances facilitate commercialization of MCC in Japan
Japanese Patent No. 04335435 entitled, "Composition and Method for Regulating Cell Proliferation and Cell Death", was issued on July 3, 2009. Japanese patent No. 4215429 entitled, "Hyaluronic Acid in the Treatment of Cancer", was issued on November 14, 2008 and covers composition claims related to combinations of hyaluronic acid and Mycobacterium phlei DNA (M-DNA), MCC or specified oligonucleotides. Japanese Patent No. 4380922 entitled, "Chemotherapeutic Composition and Method", was issued on October 2, 2009. This patent's claims relate to medicament compositions of MCC or M-DNA and a chemotherapeutic agent for inhibiting the growth of animal or human cancer cells, including leukemia, lymphoma and melanoma.
"The issuance of MCC patents in Japan provides a firm foundation for commercializing MCC in Japan - first as a treatment for bladder cancer," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.